| ||||||||||||||||||
| These SM22a-tTA/TRE-RVCH-HA bi-transgenic mice allow targeted overexpression or Tet-Off conditional expression of vascular chymase in smooth muscle cells, and may be useful in studying the role of elevated chymase activity in systemic hypertension and cardiovascular disease. | ||||||||||||||||||
- Description
- Phenotype
- Genes & alleles
- Genotyping
- Health & husbandry
- References
- Purchasing information
- Terms of Use
Description
The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.
Strain Information
Type Mutant Stock; Transgenic; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Species laboratory mouse Donating Investigator Marlene Rabinovitch, Stanford University School of Medicine Description
Hemizygous tTA+/RVCH+ (or SM22a-tTA/TRE-RVCH-HA) mice are viable and fertile, harboring two transgenes using the Tet-Off system. The SM22a-tTA transgene has the 3 kb SM22alpha promoter directing expression of the tetracycline transactivator gene (tTA) to vascular smooth muscle cells (SMCs). The TRE-RVCH-HA transgene has the tetracycline-responsive element (TRE; also called tet-operator or tetO) controlling expression of a rat vascular chymase-hemagglutinin tag (RVCH-HA) fusion gene. In the absence of tetracycline (or its analog doxycycline (dox)), the SM22alpha promoter limits RVCH-HA fusion protein expression to vascular SMCs. This RVCH overexpression results in hypertension. Because this binary transgenic system also allows for a second level of control, i.e. addition of dox, expression of the RVCH-HA fusion protein can be completely abolished; reversing the hypertension phenotype. These SM22a-tTA/TRE-RVCH-HA bi-transgenic mice allow targeted overexpression or Tet-Off conditional expression of vascular chymase in smooth muscle cells, and may be useful in studying the role of elevated chymase activity in systemic hypertension and cardiovascular disease.Development
These mice harbor two transgenes using the Tet-Off system; SM22a-tTA and TRE-RVCH-HA. The SM22a-tTA transgene was designed with the 3 kb SM22alpha (transgelin or Tagln) promoter fragment upstream of the tetracycline transactivator gene (tTA). This construct was used to create transgenic mice on a C57BL/6 genetic background. The TRE-RVCH-HA transgene was designed with the tetracycline-responsive element (TRE; also called tet-operator or tetO) upstream of a rat vascular chymase (RVCH or Mcpt1) gene (modified such that a human influenza hemagglutinin (HA) tag is added to the C terminus of mature RVCH protein). This construct was used to create transgenic mice on an "SJL/B6" genetic background. These mice were next backcrossed to C57BL/6 mice for two to three generations and subsequently bred with the SM22a-tTA transgenic mice to generate bi-transgenic offspring (SM22a-tTA/TRE-RVCH-HA). These SM22a-tTA/TRE-RVCH-HA mice were maintained on a mixed SJL and C57BL/6 genetic background by breeding to wild-type siblings for at least 16 generations prior to arrival at The Jackson Laboratory. Upon arrival, these mice may have been bred with B6SJLF1/J (Stock No. 100012) hybrid mice to maintain the colony.
Control Information
| Control | ||
|---|---|---|
| Noncarrier | ||
| 100012 B6SJLF1/J | (approximate) | |
| Considerations for Choosing Controls | ||
Related Strains
Strains carrying other alleles of Tagln
006878 B6.129S6-Taglntm2(cre)Yec/J 006875 FVB/N-Tg(Tagln-rtTA)E1Jwst/J 004746 STOCK Tg(Tagln-cre)1Her/J View Strains carrying other alleles of Tagln (3 strains)
007004 B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ 003767 B6.Cg-Tg(Eno2tTA)5021Nes/J 003763 B6.Cg-Tg(Eno2tTA)5030Nes/J 005964 B6.Cg-Tg(GFAP-tTA)110Pop/J 002618 B6.Cg-Tg(MMTVtTA)1Mam/J 008284 B6.Cg-Tg(Scg2-tTA)1Jt/J 006361 B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J 003563 B6.Cg-Tg(tTALap)5Bjd/J 002709 B6;C3-Tg(TettTALuc)1Dgs/J 003010 B6;CBA-Tg(Camk2a-tTA)1Mmay/J 008344 B6;DBA-Tg(Fos-tTA,Fos-EGFP*)1Mmay Tg(tetO-lacZ,tTA*)1Mmay/J 010573 B6;SJL-Tg(Prl-tTA)6-5Jek/J 005625 FVB-Tg(Pcp2-tTA)3Horr/J 003170 FVB.Cg-Tg(Myh6-tTA)6Smbf/J 006209 FVB.Cg-Tg(Tal1-tTA)19Dgt/J 005942 FVB/N-Tg(Pf4-tTA/VP16)42Kra/J 004937 NOD.Cg-Tg(Ins2-tTA)1Doi/DoiJ 006999 STOCK Dbttm1Geh Tg(tTALap)5Bjd Tg(tetO-DBT)A1Geh/J 009606 STOCK Tg(Six2-EGFP/cre)1Amc/J 003271 STOCK Tg(tTAhCMV)3Bjd/J 003275 STOCK Tg(tetL)1Bjd/J 003274 STOCK Tg(tetNZL)2Bjd/J
Additional Web Information
Tet Expression Systems
Phenotype
Phenotype Information
assigned by genotype
Tg(Tagln-tTA)1Mrab/0 Tg(tetO-Mcpt1)1Mrab/0
involves: C57BL/6 * SJL
- cardiovascular system phenotype
- abnormal artery morphology (MGI Ref ID J:70031)
- medial to lumen ratio of mesenteric artery is increased by 93% compared to single transgenic controls; thickening is reversed by doxycycline-induced suppression of transgene expression
- abnormal aorta morphology (MGI Ref ID J:70031)
- increase in media to lumen ratio of aorta is observed in binary transgenic mice
- abnormal vasoconstriction (MGI Ref ID J:70031)
- endothelium-dependent (methacholine-induced) relaxation in pre-constricted arteries is impaired relative to controls
- increased vasoconstriction (MGI Ref ID J:70031)
- isolated mesenteric arteries display significantly enhanced constriction in response to phenylephrine treatment relative to control arteries
- increased left ventricle weight (MGI Ref ID J:70031)
- modest increase in left ventricle weight to body weight is observed in transgene expressing mice
- increased mean arterial blood pressure (MGI Ref ID J:70031)
- MAP is increased to 103 mm Hg compared to 82 mm Hg in controls
- increased systolic blood pressure (MGI Ref ID J:70031)
- increased by an average of 27 mm Hg relative to littermate controls; 24% increase in blood pressure in double mutants is seen compared to single transgenic mice
- doxycycline treatment to suppress transgene expression completely reverses increase, returning blood pressure to control values
- cellular phenotype
- increased cell proliferation (MGI Ref ID J:70031)
- abundant expression of proliferating cells is observed of medial layer of mesenteric artery in double mutants
- muscle phenotype
- abnormal vasoconstriction (MGI Ref ID J:70031)
- endothelium-dependent (methacholine-induced) relaxation in pre-constricted arteries is impaired relative to controls
- increased vasoconstriction (MGI Ref ID J:70031)
- isolated mesenteric arteries display significantly enhanced constriction in response to phenylephrine treatment relative to control arteries
This mouse can be used to support research in many areas including:
Cardiovascular Research
Hypertension
normotensive
Research Tools
Cardiovascular Research
Tetop Tet System
Genetics Research
Mutagenesis and Transgenesis: Tetop Tet System
Tet Expression Systems
tTA/rtTA Expressing Strains
tTA/rtTA Responsive Strains
Genes & Alleles
Gene & Allele Information
| Allele Symbol | Tg(Tagln-tTA)1Mrab | ||
|---|---|---|---|
| Allele Name | transgene insertion 1, Marlene Rabinovitch | ||
| Allele Type | Transgenic (random, expressed) | ||
| Common Name(s) | SM22alpha- tTA; tTA+; | ||
| Strain of Origin | C57BL/6 | ||
| Site of Expression | vascular smooth muscle cells (SMCs) | ||
| Expressed Gene | tTA, tetracycline-controlled transactivator, E. coli | ||
| The tetracycline-resistance gene (TetR), arose from chemically mutated Escherichia coli genome which was screened for tetracycline dependence (Gossen and Bujard, 1992). TetR was fused at the C-terminus with the viral co-activator, virion protein 16 of the herpes simplex virus (VP-16). The tetracycline-inhibitable transcription factor is a component of a bigenic system that allows doxycycline (a tetracycline analog) regulatable expression of genes that are under the direction of the tetracycline responsive promoter (TetOp)promoter. | |||
| Promoter | Tagln, transgelin, mouse, laboratory | ||
| Molecular Note | Sequence encoding a tetracycline transactivator was adjoined to the smooth muscle cell specific transgelin promoter. The promoter was reported to drive expression in the aorta, but not in the heart, lung, kidney, bladder, intestine, or stomach. [MGI Ref ID J:70031] | ||
| Allele Symbol | Tg(tetO-Mcpt1)1Mrab | ||
| Allele Name | transgene insertion 1, Marlene Rabinovitch | ||
| Allele Type | Transgenic (random, expressed) | ||
| Common Name(s) | RVCH+; TRE-RVCH-HA; | ||
| Site of Expression | As the tetracycline-responsive element (TRE; also called tet-operator or tetO) controls expression of the rat vascular chymase-hemagglutinin tag (RVCH-HA) fusion gene, RVCH-HA expression is spatially and temporally dependent upon exposure to tetracycline transactivator (tTA). | ||
| Expressed Gene | Mcpt1, mast cell protease 1, rat | ||
| Promoter | tetO, tet operator, | ||
| Molecular Note | The transgene was designed with the tetracycline-responsive element (TRE; also called tet-operator or tetO) upstream of a rat vascular chymase (RVCH or Mcpt1) gene modified such that a human influenza hemagglutinin (HA) tag is added to the C terminus ofmature RVCH protein. With ddition of dox expression of the RVCH-HA fusion protein can be completely abolished, reversing the hypertension phenotype. [MGI Ref ID J:70031] | ||
Genotyping
Genotyping Information
Genotyping Protocols
Tg(TagIn-tTA)1Mrab, Standard PCR
Tg(tetO-Mcpt1)1Mrab, Standard PCR
Helpful Links
Genotyping resources and troubleshooting
References
References
Selected Reference(s)
Ju H; Gros R; You X; Tsang S; Husain M; Rabinovitch M. 2001. Conditional and targeted overexpression of vascular chymase causes hypertension in transgenic mice. Proc Natl Acad Sci U S A 98(13):7469-74. [PubMed: 11416217] [MGI Ref ID J:70031]
Additional References
Tg(Tagln-tTA)1Mrab relatedEl-Bizri N; Wang L; Merklinger SL; Guignabert C; Desai T; Urashima T; Sheikh AY; Knutsen RH; Mecham RP; Mishina Y; Rabinovitch M. 2008. Smooth muscle protein 22alpha-mediated patchy deletion of Bmpr1a impairs cardiac contractility but protects against pulmonary vascular remodeling. Circ Res 102(3):380-8. [PubMed: 18079409] [MGI Ref ID J:141529]
Gros R; Afroze T; You XM; Kabir G; Van Wert R; Kalair W; Hoque AE; Mungrue IN; Husain M. 2003. Plasma membrane calcium ATPase overexpression in arterial smooth muscle increases vasomotor responsiveness and blood pressure. Circ Res 93(7):614-21. [PubMed: 12933703] [MGI Ref ID J:128144]
Health & husbandry
The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.
Health & Colony Maintenance Information
Colony Maintenance
Breeding & Husbandry When maintaining a live colony, mice hemizygous for both transgenes may be bred together, to wildtype siblings, or to B6SJLF1/J (Stock No. 100012) inbred mice. It may be useful to maintain mice on doxycycline-treated water to avoid hypertension or other incidental effects of tTA or RVCH expression.
Purchasing information
Pricing, Supply Level & Notes, Controls, General Terms & Conditions
Pricing
| Pricing for USA, Canada and Mexico shipping destinations |
|
Animals Provided
Price (US dollars $) Cryorecovery Fee $1900.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Additional Supply Details
| Pricing for International shipping destinations |
|
Animals Provided
Price (US dollars $) Cryorecovery Fee $2470.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Additional Supply Details
|
|
|
Supply Details
| Standard Supply | Cryopreserved. Ready for recovery. Please refer to pricing and supply notes for further information. |
|---|---|
| Supply Notes |
|
Control Information
| Control | ||
|---|---|---|
| Noncarrier | ||
| 100012 B6SJLF1/J | (approximate) | |
| Considerations for Choosing Controls | ||
| USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
| International - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
Payment Terms and Conditions
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
See Terms of Use tab for General Terms and Conditions
The Jackson Laboratory's Genotype Promise
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.Ordering and Purchasing Information
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form
Terms of Use
Terms of Use
General Terms and Conditions
Use of the Tet-System may require a license, see Licenses for Strains Using TET-System Technology.
For additional Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
Contact information
General inquiries
Contracts Administration
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
JAX® Mice, Products & Services Conditions of Use
"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.No Warranty
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
No Liability
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. In purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.